AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15193553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondamped DILE
Number of subjects: 24
Study 15193553 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 11164324 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention including assessment and a personalized program with realistic manageable goals for lifestyle change and overcoming barriers using brief motivational interviewing.
Number of subjects: 0
Study 11164324 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 9725760 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ASA medication
Number of subjects: 25
Study 8054075 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric arm work
Number of subjects: 14
Study 8054075 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric leg exercise
Number of subjects: 14
Study 2608542 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational (experimental) group
Number of subjects: 36
Study 2608542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 2608542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 4616805 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole
Number of subjects: 38
Study 4616805 — intervention group
Group type: COMPARATOR
Intervention: Dichloralphenazone
Number of subjects: 38
Study 4616805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31128924 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 537
Study 31128924 — intervention group
Group type: COMPARATOR
Intervention: Avoid antiplatelet therapy
Number of subjects: 537
Study 28735829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Mat Group (PMG)
Number of subjects: 98
Study 28735829 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipment Based Pilates Group (PAG)
Number of subjects: 98
Study 28735829 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 98
Study 25354720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks for up to 24 months, combined with bicalutamide 80 mg orally every day and goserelin acetate 10.8 mg subcutaneously every 12 weeks.
Number of subjects: 53
Study 25354720 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid combined with androgen-deprivation therapy.
Number of subjects: 53
Study 24643488 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 contacts with a promotora (community health worker), consisting of 11 home visits and three telephone calls
Number of subjects: 361
Study 24643488 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 contacts with a promotora (community health worker)
Number of subjects: 361
Study 24643488 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment intervention
Number of subjects: 361
Study 21983612 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpastes with natural compounds
Number of subjects: 56
Study 18459180 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 48
Study 18459180 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy (WBRT)
Number of subjects: 48
Study 16441247 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term AED therapy (6 months)
Number of subjects: 206
Study 16441247 — intervention group
Group type: COMPARATOR
Intervention: Long-term AED therapy (2 years)
Number of subjects: 206
Study 14967268 — intervention group
Group type: EXPERIMENTAL
Intervention: Round-edged optic IOL
Number of subjects: 71
Study 14967268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp-edged optic IOL
Number of subjects: 71
Study 14967268 — intervention group
Group type: EXPERIMENTAL
Intervention: Angulated IOLs
Number of subjects: 71
Study 14967268 — intervention group
Group type: COMPARATOR
Intervention: Nonangulated silicone IOL
Number of subjects: 71
Study 11384687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin 10 units/10 mL of normal saline
Number of subjects: 51
Study 11384687 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) 10 mL
Number of subjects: 51
Study 9401425 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone that differed from preceding stimuli in the conjunction of two features
Number of subjects: 0
Study 9401425 — intervention group
Group type: COMPARATOR
Intervention: Preceding stimuli with different combinations of features
Number of subjects: 0
Study 8427657 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet (342 mmol NaCl/day)
Number of subjects: 14
Study 8427657 — intervention group
Group type: COMPARATOR
Intervention: Low salt diet (34 mmol NaCl/day)
Number of subjects: 14
Study 3309050 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response elicitation (20 minutes per day until surgery)
Number of subjects: 49
Study 3309050 — intervention group
Group type: COMPARATOR
Intervention: Reading (20 minutes per day)
Number of subjects: 49
Study 30454034 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Air Warming (FAW)
Number of subjects: 8630
Study 30454034 — intervention group
Group type: COMPARATOR
Intervention: Resistive Fabric Warming (RFW)
Number of subjects: 8630
Study 28662957 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 120
Study 28662957 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 120
Study 26193978 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 20
Study 26193978 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg
Number of subjects: 20
Study 26193978 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg
Number of subjects: 20
Study 23431213 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 148
Study 23431213 — intervention group
Group type: COMPARATOR
Intervention: Back School method
Number of subjects: 148
Study 21939510 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid for two weeks
Number of subjects: 48
Study 21939510 — intervention group
Group type: COMPARATOR
Intervention: Placebo for two weeks
Number of subjects: 48
Study 21939510 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bid
Number of subjects: 48
Study 21939510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18312764 — intervention group
Group type: EXPERIMENTAL
Intervention: fluvastatin XL 80 mg/day
Number of subjects: 199
Study 18312764 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg/day
Number of subjects: 199
Study 18312764 — intervention group
Group type: EXPERIMENTAL
Intervention: fluvastatin XL 80 mg/day plus ezetimibe 10 mg/day
Number of subjects: 199
Study 16361021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexanabinol (150 mg intravenous dose within 6 hours of injury)
Number of subjects: 861
Study 16361021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study 16361021 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Number of subjects: 861
Study 12540407 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS treatment
Number of subjects: 12
Study 12540407 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 12
Study 12540407 — intervention group
Group type: EXPERIMENTAL
Intervention: scFOS treatment (subgroup >6 years postmenopause)
Number of subjects: 12
Study 12540407 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (subgroup >6 years postmenopause)
Number of subjects: 12
Study 11046201 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemaccel-Ringer's prime
Number of subjects: 22
Study 11046201 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalyte 148
Number of subjects: 22
Study 8677723 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20-60 mg daily, usually 30-40 mg)
Number of subjects: 21
Study 8677723 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 21
Study 1522841 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (0.02 mg/kg)
Number of subjects: 1280
Study 1522841 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.2 mg/kg)
Number of subjects: 1280
Study 6430605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mestranol 24 micrograms daily
Number of subjects: 16
Study 6430605 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 16
Study 30499871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 180
Study 30499871 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine
Number of subjects: 180
Study 30499871 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 180
Study 29862494 — intervention group
Group type: EXPERIMENTAL
Intervention: VHA's Quality Enhancement Research Initiative and Health Services Research and Development Service program evaluations
Number of subjects: 0
Study 27075674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Number of subjects: 176
Study 27075674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 25268962 — intervention group
Group type: EXPERIMENTAL
Intervention: Current PPI use (within 90 days)
Number of subjects: 1830
Study 25268962 — intervention group
Group type: EXPERIMENTAL
Intervention: Current PPI use among patients receiving diuretics
Number of subjects: 1830
Study 25268962 — intervention group
Group type: EXPERIMENTAL
Intervention: Current PPI use among patients not receiving diuretics
Number of subjects: 1830
Study 25268962 — intervention group
Group type: COMPARATOR
Intervention: Histamine H2 receptor antagonists
Number of subjects: 1830
Study 22427558 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the use of closed-circuit television (CCTV) combined with delivery instructions
Number of subjects: 122
Study 22427558 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit television (CCTV)
Number of subjects: 122
Study 22427558 — intervention group
Group type: COMPARATOR
Intervention: Control group (delivery instructions only)
Number of subjects: 122
Study 22427558 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTV usage over time
Number of subjects: 122
Study 20931799 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist started when leading follicle reached 14mm
Number of subjects: 90
Study 20931799 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist started when leading follicle reached 16mm
Number of subjects: 90
Study 20931799 — intervention group
Group type: COMPARATOR
Intervention: Control group without GnRH antagonist
Number of subjects: 90
Study 16987898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined photodynamic therapy (PDT) with intravitreal triamcinolone (IVTA)
Number of subjects: 22
Study 16987898 — intervention group
Group type: COMPARATOR
Intervention: PDT monotherapy
Number of subjects: 22
Study 16987898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PDT with IVTA
Number of subjects: 22
Study 15692919 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal doses of dopamine in the postoperative period
Number of subjects: 67
Study 15692919 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal doses of dopamine in the preoperative period
Number of subjects: 67
Study 15692919 — intervention group
Group type: COMPARATOR
Intervention: Control group (100 patients)
Number of subjects: 67
Study 12495822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (150 subjects)
Number of subjects: 303
Study 12495822 — intervention group
Group type: COMPARATOR
Intervention: Control group (153 subjects)
Number of subjects: 303
Study 10193730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 93
Study 10193730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 7763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (50 mg/kg per day subcutaneously for 12 months)
Number of subjects: 110
Study 7763202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 7763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (in subgroup of 81 patients with limb onset)
Number of subjects: 110
Study 7763202 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in subgroup of 81 patients with limb onset)
Number of subjects: 110
Study 7763202 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (in bulbar subgroup of 29 patients)
Number of subjects: 110
Study 7763202 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in bulbar subgroup of 29 patients)
Number of subjects: 110
Study 2187014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone/sulbactam
Number of subjects: 152
Study 2187014 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin/clindamycin
Number of subjects: 152
Study 438014 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of dry air at various temperatures (subzero to 80 degrees C) during exercise
Number of subjects: 0
Study 438014 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of dry air at temperatures above 37 degrees C
Number of subjects: 0
Study 438014 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of small amounts of water vapor to inspirate at high temperatures
Number of subjects: 0
Study 30554925 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine periarticular injection (PAI)
Number of subjects: 59
Study 30554925 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care protocol (conventional bupivacaine PAI)
Number of subjects: 59
Study 28030470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal root ganglion stimulation (DRG)
Number of subjects: 152
Study 28030470 — intervention group
Group type: COMPARATOR
Intervention: Dorsal column stimulation (spinal cord stimulation, SCS)
Number of subjects: 152
Study 26352288 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased rigidity
Number of subjects: 231
Study 26352288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity (moderate or worse)
Number of subjects: 231
Study 26352288 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference with work
Number of subjects: 231
Study 26352288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremor
Number of subjects: 231
Study 26352288 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor impairments
Number of subjects: 231
Study 24435244 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg Oramorph® (morphine sulphate)
Number of subjects: 41
Study 24435244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 21901396 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and 5-azacytidine 75 mg/m2 daily on days 1-4 and 15-18 of a 28-day cycle
Number of subjects: 30
Study 18369376 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 100
Study 18369376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pascal dynamic contour tonometer (PDCT)
Number of subjects: 100
Study 18369376 — intervention group
Group type: COMPARATOR
Intervention: Both GAT and PDCT
Number of subjects: 100
Study 17309589 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% povidone-iodine
Number of subjects: 60
Study 17309589 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 60
Study 15371784 — intervention group
Group type: EXPERIMENTAL
Intervention: Body temperature (BT) saline
Number of subjects: 91
Study 15371784 — intervention group
Group type: COMPARATOR
Intervention: Room temperature (RT) saline
Number of subjects: 91
Study 11856085 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 240
Study 11856085 — intervention group
Group type: COMPARATOR
Intervention: Butyl scopolamine bromide (SC group)
Number of subjects: 240
Study 11856085 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose administration
Number of subjects: 240
Study 11856085 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (in complicated patients, GC group)
Number of subjects: 240
Study 9951595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 20
Study 9951595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus mometasone furoate
Number of subjects: 20
Study 7788232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound transmission velocity (UTV) measurement
Number of subjects: 313
Study 7788232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurement
Number of subjects: 313
Study 7788232 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic (ROC) curve analysis for UTV
Number of subjects: 313
Study 2170893 — intervention group
Group type: EXPERIMENTAL
Intervention: medium flavoring with medium tartar control (toothpaste B)
Number of subjects: 92
Study 2170893 — intervention group
Group type: EXPERIMENTAL
Intervention: high flavoring with medium tartar control (toothpaste C)
Number of subjects: 92
Study 2170893 — intervention group
Group type: COMPARATOR
Intervention: control‐low flavor with no tartar control (toothpaste A)
Number of subjects: 92
Study 2170893 — intervention group
Group type: COMPARATOR
Intervention: medium flavoring with no tartar control (toothpaste D)
Number of subjects: 92
Study 103190 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐penicillamine (600 mg daily for one year)
Number of subjects: 100
Study 103190 — intervention group
Group type: COMPARATOR
Intervention: Gold (sodium aurothiomalate 50 mg weekly up to a total of 13 mg/kg, then 50 mg once a month for one year)
Number of subjects: 100
Study 28922213 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic resistance using a load cell (LC) that displays force during exercise
Number of subjects: 0
Study 28922213 — intervention group
Group type: COMPARATOR
Intervention: Elastic resistance only
Number of subjects: 0
Study 29237906 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy group (NRG) - 2000-3000 cGy 192 Ir irradiation of preoperatively intracavitary brachytherapy
Number of subjects: 78
Study 29237906 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone group (SAG)
Number of subjects: 78
Study 25463545 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin (1.5 g/kg on day 1 and 1g/kg on day 3)
Number of subjects: 193
Study 25463545 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (control group)
Number of subjects: 193
Study 25463545 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus albumin
Number of subjects: 193
Study 23572482 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening (study staff screened using culture and commercial PCR)
Number of subjects: 607
Study 23572482 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening (first PCR)
Number of subjects: 607
Study 23572482 — intervention group
Group type: COMPARATOR
Intervention: Passive screening (nonintervention arm; observation with local standard of care)
Number of subjects: 607
Study 21327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine ER 30 mg o.d. as monotherapy (MT)
Number of subjects: 1849
Study 21327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine ER 30 mg o.d. as add-on to α-blockers (CT)
Number of subjects: 1849
Study 21327673 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine ER treatment
Number of subjects: 1849
Study 19617815 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) treatment with antiretroviral therapy (nucleoside analogues) for 12 months
Number of subjects: 97
Study 19617815 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy alone for 12 months
Number of subjects: 97
Study 19617815 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 experienced adults on highly active antiretroviral therapy
Number of subjects: 97
Study 15740555 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 640 mg
Number of subjects: 24
Study 15740555 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐MPS 720 mg
Number of subjects: 24
Study 15740555 — intervention group
Group type: COMPARATOR
Intervention: MMF 1000 mg
Number of subjects: 24
Study 10321417 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen, aspirin, and caffeine (AAC)
Number of subjects: 1220
Study 8597320 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training program
Number of subjects: 24
Study 8597320 — intervention group
Group type: COMPARATOR
Intervention: Nonexercising control group
Number of subjects: 24
Study 1820903 — intervention group
Group type: EXPERIMENTAL
Intervention: New Levothyroxine solution
Number of subjects: 12
Study 1820903 — intervention group
Group type: COMPARATOR
Intervention: Reference L-thyroxine solution
Number of subjects: 12
Study 7042486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 100
Study 7042486 — intervention group
Group type: COMPARATOR
Intervention: Caved-S (six tablets daily)
Number of subjects: 100
Study 31939235 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-fracture therapy combined with intra-articular injection of PRP
Number of subjects: 43
Study 31939235 — intervention group
Group type: COMPARATOR
Intervention: Micro-fracture therapy
Number of subjects: 43
Study 31032717 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX-mCIMT
Number of subjects: 64
Study 31032717 — intervention group
Group type: COMPARATOR
Intervention: BTX-ICT
Number of subjects: 64
Study 29273337 — intervention group
Group type: EXPERIMENTAL
Intervention: QR evaluations
Number of subjects: 161
Study 26803236 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months DAPT
Number of subjects: 429
Study 26803236 — intervention group
Group type: COMPARATOR
Intervention: 12 months DAPT
Number of subjects: 429
Study 23779051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 nights of 4h sleep
Number of subjects: 25
Study 23779051 — intervention group
Group type: COMPARATOR
Intervention: 5 nights of 9h sleep
Number of subjects: 25
Study 23779051 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 nights of restricted sleep (4h)
Number of subjects: 25
Study 22584491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg Pidolate (MgP) 3.0 g/day for 30 days (equivalent to 260 mg of Mg element)
Number of subjects: 60
Study 22584491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 60